Loading…
Loading…
ROCHESTER, N.Y.--(BUSINESS WIRE)--Eastman Kodak Company today announced the expansion of its KODAK PHARMACEUTICALS portfolio with the addition of KODAK® Normal Saline, 0.9%. The company also introduced a new U.S.-based online store designed to simplify purchasing for pharmaceutical, biotech, and life science customers.
ROCHESTER, N.Y.--(BUSINESS WIRE)--Eastman Kodak Company Third-Quarter 2026 Earnings Conference Call.
The S&P 500 recently sat just 2.5% below its all-time high. Look past the index, though, and the picture gets uglier.
Eastman Kodak is executing a credible turnaround, with strong revenue and margin improvements, particularly in its Advanced Materials & Chemicals (AM&C) segment. KODK posted 18% y/y revenue growth in Q2 '26, with AM&C up 40% and gross margins expanding 700 bps to 26.4%, signaling operational momentum. The balance sheet has strengthened with $290 million in cash and $110 million in debt, though cash flow remains a concern due to inventory buildup and higher silver prices.
Counterpoint Mutual Funds LLC acquired a new position in Eastman Kodak Company (NYSE: KODK) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 81,274 shares of the technology company's stock, valued at approximately $777,000. Counterpoint Mutual Funds LLC
KODK and NRXS are worth watching for their growth.
Eastman Kodak (NYSE: KODK) reported higher second-quarter revenue, profit and operational EBITDA, marking its fourth consecutive quarter of year-over-year gains in those measures, as growth in its Advanced Materials and Chemicals and Print businesses helped offset higher commodity costs. For the quarter ended June 30, Kodak posted revenue of $311 million, up 18% from $263 million
KODK reports a rise in Q2 profit as revenues increase 18% y/y, gross profit surges 61% and its balance sheet continues to strengthen.